Valuing health-related quality of life: An EQ-5D-5L value set for England.

Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. · 2018

Read Valuing health-related quality of life: An EQ-5D-5L value set for England. by Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6680214.txt.

Introduction

Devlin and co-authors produce an EQ-5D-5L value set for England. Their valuation study appears in Health Economics. The EQ-5D-5L describes 3,125 possible health states. Each needs a value for quality-adjusted life year calculations. Nearly a thousand English adults completed valuation tasks. They did time trade-off and discrete choice exercises. Interviews were held face to face. A hybrid model merged both data types. Pain and discomfort carried the greatest weight. Anxiety and depression followed closely.

The full range of values runs from a low of minus 0.285 for the worst states up to 0.950 for near-full health. Just over five percent of states rate worse than dead. The older 3L set put over a third there. Gains from treating very poor health shrink accordingly. Earlier estimates may have overstated such benefits.

Catalog record

CREATORDevlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE56 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6680214

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Valuing health‐related quality of life: An EQ‐5D‐5L value set for England By Nancy J Devlin, Koonal K Shah, Yan Feng, Brendan Mulhern, Ben van Hout Published in: Health Economics DOI: 10.1002/hec.3564 ABSTRACT Abstract A new version of the EQ‐5D, the EQ‐5D‐5L, is available. The aim of this study is to produce a value set to support use of EQ‐5D‐5L data in decision‐making. The study design followed an international research protocol. Randomly selected members of the English general public completed 10 time trade‐off and 7 discrete choice experiment tasks in face‐to‐face interviews. A 20‐parameter hybrid model was used to combine time trade‐off and discrete choice experiment data to generate values for the 3,125 EQ‐5D‐5L health states. Valuation data are available for 996 respondents. Face validity of the data has been demonstrated, with more severe health states generally given lower values. Problems with pain/discomfort and anxiety/depression received the greatest weight. Compared to the existing EQ‐5D‐3L value set, there are considerably fewer “worse than dead” states (5.1%, compared with over one third), and the minimum value is higher. Values range from −0.285 (extreme problems on all dimensions) to 0.950 (for health states 11211 and 21111). Results have important implications for users of the EQ‐5D‐5L both in England and internationally. Quality‐adjusted life year gains from interventions seeking to improve very poor health may be smaller using this value set and may previously have been overestimated. Keywords: EQ‐5D‐5L, NICE, PROMs, quality of life, stated preferences INTRODUCTION Health care decisions are made under uncertainty, whereby any decision may have a range of different outcomes. To make the “best” decision, potential outcomes need ordering and valuing. Such decisions are made both at the individual level, such as choosing the optimal treatment for a patient, and at the national level, such as choosing how to allocate resources between treatments for different patient groups and across different health conditions. Clinical decisions often affect patients' health‐related quality of life (HRQL). Evidence on patients' HRQL can be obtained using patient‐reported outcome (PRO) measures. These may be condition specific or generic (see Fayers and Machin, 2016, and Longworth et al., 2014, for further information). Condition‐specific PROs focus on specific health problems and aim to provide detailed information about the impacts of the condition, disregarding problems that are atypical for the condition. Generic PROs aim to cover a more general spectrum of health problems and are designed to be applicable for any health condition. They can capture comorbidities and allow comparisons with population norms. Evidence obtained from generic measures can be used to compare both the impact of health problems and the benefits offered by treatments across different patient populations and disease areas. This makes these data particularly useful for informing decisions made by health care professionals, commissioners, regulators, health technology assessment bodies (such as the National Institute for Health and Care Excellence [NICE]), payers, and budget holders. The EQ‐5D is the most widely used generic PRO questionnaire internationally (Devlin & Brooks, 2017; Richardson, McKie, & Bariola, 2014). It is the instrument recommended by NICE for evidence submitted to its technology appraisal process (NICE, 2013). It has also proved useful in population health surveys and in the English National Health Service (NHS) patient‐reported outcome measures programme (Devlin & Appleby, 2010). The EQ‐5D asks patients to indicate whether they have no, some, or extreme problems on each of five dimensions of health: mobility, self‐care, usual activities, pain/discomfort, and anxiety/depression. The EQ‐5D is a valid and reliable measure in many disease areas (Janssen, Lubetkin, Sekhobo, & Pickard, 2011; Pickard, Wilke, Lin, & Lloyd, 2007; Wailoo, David, & Tosh, 2010). However, there have been concerns that three response options for each dimension may not adequately capture milder health problems experienced by patients, and smaller changes between different health states. A new version of the instrument, the EQ‐5D‐5L, was developed to improve sensitivity and to standardise the language used across dimensions (Herdman et al., 2011). The EQ‐5D‐5L comprises the same five dimensions, but increases the available response options (levels) from three to five (no, slight, moderate, severe, and extreme problems/unable to)—see Figure 1. The five dimensions and five levels of the EQ‐5D‐5L describe 3,125 (55) unique health states, compared to the 243 (35) described by the EQ‐5D. [Figure: The EQ‐5D‐5L descriptive system] The EQ‐5D‐5L is rapidly being incorporated into routine data collection in clinical settings, clinical trials and population health surveys, such as the GP patient survey (NHS, 2016) and the Health Survey for England (Fuller, Mindell, & Prior, 2016). It is also used in local initiatives. For example, the Cambridgeshire Community Services NHS Trust collects EQ‐5D‐5L data to evaluate outcomes from rehabilitation services (Cambridgeshire Community Services NHS Trust, 2013–2014). Its design accounts for the need for a direct link between the measurement and valuation of health, whereby every health state that patients might report on the EQ‐5D‐5L instrument can be summarised by a single value. In order to be used in the calculation of quality‐adjusted life years (QALYs; a metric used in cost‐utility analysis that combines survival and HRQL), these values need to summarise how good or bad each health state is on a scale anchored at 1 (full health) and 0 (a state equivalent to dead). Values less than 0 represent health states considered to be or modelled as worse than dead. The values are based on the views of the general public who are asked to imagine living in various health states and to respond to a series of structured questions designed to find out the importance to them of different aspects of health. This approach follows the requirements of NICE (2013) and similar organisations (e.g., Australia's Pharmaceutical Benefits Advisory Committee, 2016, and the Canadian Agency for Drugs and Technologies in Health, 2006) for the use of EQ‐5D‐5L data in decision‐making and reflects a belief that it is the views of the general public—as taxpayers and potential users of health care—that should count, rather than simply those of patients (Neumann, Ganiats, Russell, Sanders, & Siegel, 2017). At the time of writing, 25 value sets for the (three‐level) EQ‐5D‐3L are available (Devlin & Brooks, 2017), a number of which are summarised by Szende, Oppe, and Devlin (2007). The current U.K. EQ‐5D‐3L value set (Dolan, 1997)—which was developed based on data collected in the early 1990s—has values that range from 1 for no problems on any dimension to −0.594 for the worst health state (Level 3 problems on each dimension). A number of limitations have been noted with that value set. Among these are that approximately a third of health states described by the EQ‐5D‐3L were assigned negative values, meaning those health states are valued as being worse than dead. Although this may reflect genuine preferences, it is worth noting that the U.K. EQ‐5D‐3L values are rather unique in this respect: all other countries have fewer worse than dead health states and higher minimum values. Another generic measure with a U.K. value set—the SF‐6D (Brazier, Roberts, & Deverill, 2002)—includes no health states valued as worse than dead. Additionally, although also common to other countries, any change in health away from full health to “some” problems, on any aspect of health, results in a large fall in the overall value (of at least 0.12, meaning that the

Read the complete text